pramipexole + Bromocriptine

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Feb 1, 2012 → May 23, 2016

NCT ID

NCT01673724

About pramipexole + Bromocriptine

pramipexole + Bromocriptine is a approved stage product being developed by Sandoz Group for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01673724. Target conditions include Parkinson's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease were approved

Approved (20) Terminated (3) Active (0)

✅Lemborexant + placeboEisaiApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

✅carbidopa/levodopa + Carbidopa/Levodopa/EntacaponeNovartisApproved

✅carbidopa, levodopa, entacaponeNovartisApproved

✅Levodopa/carbidopa/entacapone + Levodopa/carbidopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01673724	Approved	Completed	Feb 1, 2012	May 23, 2016	Parkinson's Disease

Competing Products

20 competing products in Parkinson's Disease

See all competitors

Product	Company	Stage	Hype Score
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
E2007 + E2007 + E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	27
E2007	Eisai	Phase 2	27
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	35
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 3	40